These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3701190)

  • 41. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
    Wood JC; Glynos T; Thompson A; Giardina P; Harmatz P; Kang BP; Paley C; Coates TD
    Am J Hematol; 2010 Oct; 85(10):818-9. PubMed ID: 20799360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda.
    Rocchi E; Gibertini P; Cassanelli M; Pietrangelo A; Borghi A; Ventura E
    J Lab Clin Med; 1986 Jan; 107(1):36-42. PubMed ID: 3941293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum iron levels in siderosis due to habitually excessive iron intake.
    HIGGINSON J; KEELEY KJ; ANDERSSON M; WALKER AR
    J Clin Invest; 1957 Dec; 36(12):1723-5. PubMed ID: 13491704
    [No Abstract]   [Full Text] [Related]  

  • 44. Patterns of pathological iron storage. I. The nature and significance of transfusional siderosis and its relationship to idiopathic hemochromatosis and allied conditions.
    WYATT JP
    AMA Arch Pathol; 1956 Jan; 61(1):42-55. PubMed ID: 13275203
    [No Abstract]   [Full Text] [Related]  

  • 45. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urine iron excretion in beta-thalassemia trait.
    Camerini G; Voghenzi A; Kalapurackal M
    Boll Soc Ital Biol Sper; 1987 Apr; 63(4):317-21. PubMed ID: 3447608
    [No Abstract]   [Full Text] [Related]  

  • 47. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy.
    Pearson HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):160-2. PubMed ID: 17356394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 50. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia.
    Musallam KM; Motta I; Salvatori M; Fraquelli M; Marcon A; Taher AT; Cappellini MD
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):136-9. PubMed ID: 22727143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S; Jabbari A; Cohan N; Haghpanah S
    Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
    Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
    Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation and treatment of transfusional iron overload in children.
    Ware HM; Kwiatkowski JL
    Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FACTORS INFLUENCING THE CLINICAL USE OF CHELATES IN IRON STORAGE DISEASE.
    WEINER M
    Ann N Y Acad Sci; 1964 Oct; 119():789-96. PubMed ID: 14219458
    [No Abstract]   [Full Text] [Related]  

  • 56. Plasma iron and iron-binding capacity in African males with siderosis.
    HATHORN M; GILLMAN T; CANHAM PA; LAMONT NM
    Clin Sci; 1960 Feb; 19():35-43. PubMed ID: 13852039
    [No Abstract]   [Full Text] [Related]  

  • 57. Serum ferritin from siderotic mice contains iron.
    Honda T; Massover WH
    Br J Haematol; 1981 Dec; 49(4):653-7. PubMed ID: 6797462
    [No Abstract]   [Full Text] [Related]  

  • 58. [LIVER SIDEROSIS AND ITS ROLE IN IRON METABOLISM BY THE HUMAN LIVER].
    MEIER-RUGE W
    Beitr Pathol Anat; 1964 Mar; 129():345-53. PubMed ID: 14186816
    [No Abstract]   [Full Text] [Related]  

  • 59. Nonspecific serum iron in thalassemia: quantitation and chemical reactivity.
    Graham G; Bates GW; Rachmilewitz EA; Hershko C
    Am J Hematol; 1979; 6(3):207-17. PubMed ID: 484544
    [No Abstract]   [Full Text] [Related]  

  • 60. [About Siderose].
    SCHNEIDER H
    Zentralbl Arbeitsmed; 1957 Jun; 7(6):142-5. PubMed ID: 13457059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.